Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 929756, 6 pages
http://dx.doi.org/10.1155/2014/929756
Research Article

Serum Fibroblast Growth Factor 21 Levels Are Correlated with the Severity of Diabetic Retinopathy

1Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
2Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China
3Key Laboratory of Biotechnology Pharmaceutical Engineering, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China
4Department of Endocrinology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 323000, China
5Department of Ophthalmology, Lishui People’s Hospital, Wenzhou Medical University, Lishui 323000, China

Received 4 February 2014; Accepted 31 March 2014; Published 15 April 2014

Academic Editor: Dimitrios Papazoglou

Copyright © 2014 Yuan Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Morello, “Etiology and natural history of diabetic retinopathy: an overview,” American Journal of Health-System Pharmacy, vol. 64, no. 17, pp. S3–S7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. K. Song, B. D. Roufogalis, and T. H. W. Huang, “Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology,” British Journal of Pharmacology, vol. 165, no. 1, pp. 4–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. T. N. Crawford, D. V. Alfaro III, J. B. Kerrison, and E. P. Jablon, “Diabetic retinopathy and angiogenesis,” Current Diabetes Reviews, vol. 5, no. 1, pp. 8–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Varma, F. Choudhury, R. Klein, J. Chung, M. Torres, and S. P. Azen, “Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study,” American Journal of Ophthalmology, vol. 149, no. 5, pp. 752–761.e3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Harris Nwanyanwu, N. Talwar, T. W. Gardner, J. S. Wrobel, W. H. Herman, and J. D. Stein, “Predicting development of proliferative diabetic retinopathy,” Diabetes Care, vol. 36, no. 6, pp. 1562–1568, 2013. View at Publisher · View at Google Scholar
  6. S. P. Davidovic, S. V. Nikolic, N. J. Curic et al., “Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy,” European Journal of Ophthalmology, vol. 22, no. 5, pp. 792–798, 2012. View at Publisher · View at Google Scholar
  7. K. Gündüz and S. J. Bakri, “Management of proliferative diabetic retinopathy,” Comprehensive Ophthalmology Update, vol. 8, no. 5, pp. 245–256, 2007. View at Google Scholar · View at Scopus
  8. M. Abbate, P. Cravedi, I. Iliev, G. Remuzzi, and P. Ruggenenti, “Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives,” Current Diabetes Reviews, vol. 7, no. 3, pp. 190–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Abhary, K. P. Burdon, A. Gupta et al., “Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 50, no. 12, pp. 5552–5558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Ruberte, E. Ayuso, M. Navarro et al., “Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease,” Journal of Clinical Investigation, vol. 113, no. 8, pp. 1149–1157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Praidou, E. Papakonstantinou, S. Androudi, N. Georgiadis, G. Karakiulakis, and S. Dimitrakos, “Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema,” Acta Ophthalmologica, vol. 89, no. 3, pp. 248–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. F. A. Zakareia, A. A. Alderees, K. A. Al Regaiy, and F. A. Alrouq, “Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy,” Journal of Diabetes and Its Complications, vol. 24, no. 3, pp. 179–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. A. Belov and M. Mohammadi, “Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology,” Cold Spring Harbor Perspectives in Biology, vol. 5, no. 6, Article ID a015958, 2013. View at Publisher · View at Google Scholar
  14. C. Canto and J. Auwerx, “Cell biology. FGF21 takes a fat bite,” Science, vol. 336, no. 6082, pp. 675–676, 2012. View at Publisher · View at Google Scholar
  15. R. Smith, A. Duguay, J. Weiszmann et al., “A novel approach to improve the function of FGF21,” BioDrugs, vol. 27, no. 2, pp. 159–166, 2013. View at Publisher · View at Google Scholar
  16. Y. Xiao, A. Xu, L. S. C. Law et al., “Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. E54–E58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Kharitonenkov, T. L. Shiyanova, A. Koester et al., “FGF-21 as a novel metabolic regulator,” Journal of Clinical Investigation, vol. 115, no. 6, pp. 1627–1635, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Lin, Q. Gong, C. Wu et al., “Dynamic change of serum FGF21 levels in response to glucose challenge in human,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 7, pp. E1224–E1228, 2012. View at Google Scholar
  19. M. Pyörälä, H. Miettinen, P. Halonen, M. Laakso, and K. Pyörälä, “Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 2, pp. 538–544, 2000. View at Google Scholar · View at Scopus
  20. M. Tomić, S. Ljubić, and S. Kastelan, “The role of inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy,” Collegium Antropologicum, vol. 37, supplement 1, pp. 51–57, 2013. View at Google Scholar
  21. Y. Yamamoto, H. Hirose, I. Saito et al., “Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population,” Clinical Science, vol. 103, no. 2, pp. 137–142, 2002. View at Google Scholar · View at Scopus
  22. R. H. Muni, R. P. Kohly, E. Q. Lee, J. E. Manson, R. D. Semba, and D. A. Schaumberg, “Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial,” JAMA Ophthalmology, vol. 131, no. 4, pp. 514–521, 2013. View at Publisher · View at Google Scholar
  23. A. C. Adams and A. Kharitonenkov, “FGF21: the center of a transcriptional nexus in metabolic regulation,” Current Diabetes Reviews, vol. 8, no. 4, pp. 285–293, 2012. View at Google Scholar
  24. S. Stein, H. Stepan, J. Kratzsch et al., “Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia,” Metabolism, vol. 59, no. 1, pp. 33–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Murata, M. Konishi, and N. Itoh, “Fgf21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology,” Journal of Nutrition and Metabolism, vol. 2011, Article ID 981315, 8 pages, 2011. View at Publisher · View at Google Scholar
  26. W. L. Holland, A. C. Adams, J. T. Brozinick et al., “An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice,” Cell Metabolism, vol. 17, no. 5, pp. 790–797, 2013. View at Publisher · View at Google Scholar
  27. Z. Lin, H. Tian, K. S. Lam et al., “Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice,” Cell Metabolismolism, vol. 17, no. 5, pp. 779–789, 2013. View at Publisher · View at Google Scholar
  28. I. Raz and B. Gallwitz, “The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue,” Review of Diabetic Studies, vol. 8, no. 3, pp. 288–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. F. Abcouwer, “Angiogenic factors and cytokines in diabetic retinopathy,” Journal of Clinical & Cellular Immunology, supplement 1, no. 11, 2013. View at Publisher · View at Google Scholar
  30. J. Zhou, S. Wang, and X. Xia, “Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy,” Current Eye Research, vol. 37, no. 5, pp. 416–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Simo, S. Roy, F. Behar-Cohen, A. Keech, P. Mitchell, and T. Y. Wong, “Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives,” Current Medicinal Chemistry, vol. 20, no. 26, pp. 3258–3266, 2013. View at Google Scholar